The pan-PPAR agonist lanifibranor combines the benefits of selective PPAR agonists by targeting all 3 PPAR isoforms and successfully reduces hepatic steatosis, inflammation, and fibrosis in MASLD mouse models.22 Here, PPARA is linked to fatty liver disease.